Skip to main content
NASDAQ:FLXN

Flexion Therapeutics News Headlines

$8.23
0.00 (0.00 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.14
$8.53
50-Day Range
$6.99
$9.67
52-Week Range
$6.71
$14.39
Volume940,111 shs
Average Volume873,721 shs
Market Capitalization$411.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64

Headlines

Flexion Therapeutics (NASDAQ FLXN) News Headlines Today

SourceHeadline
 Brokerages Anticipate Flexion Therapeutics, Inc. (NASDAQ:FLXN) Will Post Quarterly Sales of $28.02 Million Brokerages Anticipate Flexion Therapeutics, Inc. (NASDAQ:FLXN) Will Post Quarterly Sales of $28.02 Million
americanbankingnews.com - May 18 at 1:04 AM
Q2 2021 EPS Estimates for Flexion Therapeutics, Inc. (NASDAQ:FLXN) Raised by OppenheimerQ2 2021 EPS Estimates for Flexion Therapeutics, Inc. (NASDAQ:FLXN) Raised by Oppenheimer
americanbankingnews.com - May 17 at 1:44 AM
-$0.50 Earnings Per Share Expected for Flexion Therapeutics, Inc. (NASDAQ:FLXN) This Quarter-$0.50 Earnings Per Share Expected for Flexion Therapeutics, Inc. (NASDAQ:FLXN) This Quarter
americanbankingnews.com - May 16 at 10:04 PM
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare ConferenceFlexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
finance.yahoo.com - May 14 at 2:29 AM
Flexion Therapeutics (NASDAQ:FLXN) Announces  Earnings Results, Misses Expectations By $0.08 EPSFlexion Therapeutics (NASDAQ:FLXN) Announces Earnings Results, Misses Expectations By $0.08 EPS
americanbankingnews.com - May 13 at 3:44 PM
Credit Suisse Group Lowers Flexion Therapeutics (NASDAQ:FLXN) Price Target to $14.00Credit Suisse Group Lowers Flexion Therapeutics (NASDAQ:FLXN) Price Target to $14.00
americanbankingnews.com - May 13 at 12:54 PM
Flexion Therapeutics (NASDAQ:FLXN) Releases FY 2021 Earnings GuidanceFlexion Therapeutics (NASDAQ:FLXN) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 12 at 6:12 PM
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business UpdatesFlexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
finance.yahoo.com - May 12 at 6:08 PM
Head to Head Contrast: Seres Therapeutics (NASDAQ:MCRB) & Flexion Therapeutics (NASDAQ:FLXN)Head to Head Contrast: Seres Therapeutics (NASDAQ:MCRB) & Flexion Therapeutics (NASDAQ:FLXN)
americanbankingnews.com - May 11 at 11:12 PM
Earnings Preview: Flexion TherapeuticsEarnings Preview: Flexion Therapeutics
benzinga.com - May 11 at 3:33 PM
Flexion Therapeutics (NASDAQ:FLXN) & Generation Bio (NASDAQ:GBIO) Critical ContrastFlexion Therapeutics (NASDAQ:FLXN) & Generation Bio (NASDAQ:GBIO) Critical Contrast
americanbankingnews.com - May 10 at 3:06 AM
Flexion Therapeutics (FLXN) to Release Quarterly Earnings on WednesdayFlexion Therapeutics (FLXN) to Release Quarterly Earnings on Wednesday
americanbankingnews.com - May 6 at 12:46 PM
Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
finance.yahoo.com - May 5 at 9:31 PM
Flexion Therapeutics (NASDAQ:FLXN) Issues FY 2021 Earnings GuidanceFlexion Therapeutics (NASDAQ:FLXN) Issues FY 2021 Earnings Guidance
americanbankingnews.com - May 4 at 5:56 PM
Flexion Therapeutics, Inc. (NASDAQ:FLXN) Expected to Announce Quarterly Sales of $24.61 MillionFlexion Therapeutics, Inc. (NASDAQ:FLXN) Expected to Announce Quarterly Sales of $24.61 Million
americanbankingnews.com - May 1 at 4:50 AM
Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseFlexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
finance.yahoo.com - April 29 at 10:41 PM
Flexion Therapeutics, Inc. (NASDAQ:FLXN) Expected to Post Earnings of -$0.49 Per ShareFlexion Therapeutics, Inc. (NASDAQ:FLXN) Expected to Post Earnings of -$0.49 Per Share
americanbankingnews.com - April 29 at 4:28 AM
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingFlexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
finance.yahoo.com - April 28 at 10:34 AM
Flexion Therapeutics, Inc. (NASDAQ:FLXN) Receives Average Recommendation of "Buy" from AnalystsFlexion Therapeutics, Inc. (NASDAQ:FLXN) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - April 26 at 8:50 AM
Flexion Therapeutics(NASDAQ:FLXN) Share Price Is Down 61% Over The Past Three Years.Flexion Therapeutics'(NASDAQ:FLXN) Share Price Is Down 61% Over The Past Three Years.
nasdaq.com - April 17 at 1:08 AM
Thinking about buying stock in Grupo Televisa, Phunware, Immunitybio, Flexion Therapeutics, or Amicus Therapeutics?Thinking about buying stock in Grupo Televisa, Phunware, Immunitybio, Flexion Therapeutics, or Amicus Therapeutics?
marketwatch.com - April 16 at 10:04 AM
Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call TranscriptFlexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript
finance.yahoo.com - April 14 at 6:09 PM
Would Shareholders Who Purchased Flexion Therapeutics (NASDAQ:FLXN) Stock Three Years Be Happy With The Share price Today?Would Shareholders Who Purchased Flexion Therapeutics' (NASDAQ:FLXN) Stock Three Years Be Happy With The Share price Today?
finance.yahoo.com - April 14 at 1:09 PM
Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
finance.yahoo.com - April 13 at 5:07 PM
Flexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare ConferenceFlexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare Conference
finance.yahoo.com - April 8 at 9:26 PM
Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative PainFlexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain
finance.yahoo.com - March 31 at 8:51 AM
The Right Call On Frustrating Flexion TherapeuticsThe Right Call On Frustrating Flexion Therapeutics
seekingalpha.com - March 30 at 12:49 PM
Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare ConferenceFlexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference
finance.yahoo.com - March 15 at 12:57 PM
Flexion Therapeutics, Inc. 2020 Q4 - Results - Earnings Call PresentationFlexion Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 15 at 9:24 AM
Flexion Therapeutics Inc (FLXN) Q4 2020 Earnings Call TranscriptFlexion Therapeutics Inc (FLXN) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 11 at 8:49 AM
Flexion Therapeutics (FLXN) Reports Q4 Loss, Misses Revenue EstimatesFlexion Therapeutics (FLXN) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 11 at 12:45 AM
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial ResultsFlexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results
finance.yahoo.com - March 10 at 7:44 PM
Flexion Therapeutics: Q4 Earnings InsightsFlexion Therapeutics: Q4 Earnings Insights
finance.yahoo.com - March 10 at 7:44 PM
Flexion Therapeutics, Inc. to Host Earnings CallFlexion Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 10 at 2:43 PM
Flexion Therapeutics Reports Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 5 at 5:41 PM
Will Flexion Therapeutics (FLXN) Report Negative Q4 Earnings? What You Should KnowWill Flexion Therapeutics (FLXN) Report Negative Q4 Earnings? What You Should Know
finance.yahoo.com - March 4 at 1:45 PM
Flexion shares gain 4% on FDA clearance of FX301 in post-operative painFlexion shares gain 4% on FDA clearance of FX301 in post-operative pain
seekingalpha.com - March 4 at 3:09 AM
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021
finance.yahoo.com - March 3 at 5:08 PM
Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal SurgeryFlexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery
finance.yahoo.com - March 1 at 5:38 PM
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative PainFlexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain
finance.yahoo.com - March 1 at 7:37 AM
Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors ConferenceFlexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference
finance.yahoo.com - February 22 at 5:31 PM
FLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With LLYFLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With LLY
nasdaq.com - February 19 at 9:35 AM
Flexion To Test Higher Dose Of FX201 Gene Therapy In Early-Stage Osteoarthritis StudyFlexion To Test Higher Dose Of FX201 Gene Therapy In Early-Stage Osteoarthritis Study
finance.yahoo.com - February 18 at 6:31 PM
Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment GroupsFlexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups
finance.yahoo.com - February 18 at 8:30 AM
National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA(R)National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA(R)
marketwatch.com - February 2 at 7:30 AM
National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®
finance.yahoo.com - February 1 at 3:13 PM
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 ResultsFlexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
finance.yahoo.com - January 13 at 9:54 AM
Flexion Therapeutics to Present at the ICR | Westwicke Investment ConferenceFlexion Therapeutics to Present at the ICR | Westwicke Investment Conference
benzinga.com - January 7 at 5:12 PM
Is FLXN A Good Stock To Buy Now?Is FLXN A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 6:15 PM
FLXN.N - Flexion Therapeutics Inc Profile | ReutersFLXN.N - Flexion Therapeutics Inc Profile | Reuters
reuters.com - December 9 at 11:02 PM
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.